Atlas Trials

Disease, Hodgkin

9 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch Disease, Hodgkin

RecordFirmDate
A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial) (NCT01100502)Seagen Inc.2010-04-30
A Phase 1 Study of Brentuximab Vedotin Combined With Multi-Agent Chemotherapy for Hodgkin Lymphoma (NCT01060904)Seagen Inc.2010-01-01
Cardiac Safety Study of Brentuximab Vedotin (SGN-35) (NCT01026233)Seagen Inc.2010-01-01
Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35) (NCT01026415)Seagen Inc.2009-12-01
A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study (NCT00947856)Seagen Inc.2009-07-01
A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma (NCT00848926)Seagen Inc.2009-02-01
A Phase I Dose Escalation Study of SGN-35 Alone and in Combination With Gemcitabine for CD30-Positive Malignancies (NCT00649584)Seagen Inc.2008-03-01
Phase I Open-Label Dose Finding Study of SGN-35 for CD30 Positive Hematologic Malignancies (NCT00430846)Seagen Inc.2006-11-01
A Treatment-Option Protocol to Provide Brentuximab Vedotin to Eligible Patients Completing Studies SGN35-005 or C25001 (NCT01196208)Seagen Inc.

Track Disease, Hodgkin automatically

Every clearance here is in the API, with alerts when new ones post.